Stock Price
60.59
Daily Change
-1.40 -2.26%
Monthly
-6.70%
Yearly
-21.93%
Q3 Forecast
59.31

EPS Reference Time Actual Consensus Previous
2024-11-27 FY2024Q3 1.02 1.05 0.99
2024-07-31 FY2024Q2 1.00 0.92
2024-04-30 FY2024Q1 0.90 0.85
2024-02-06 FY2023Q4 1.18 1.31



Peers Price Chg Day Year Date
Supermax Corporation Bhd 0.27 0 0% -54.24% Jul/24
Hoya 24,560.00 -280.00 -1.13% 27.02% Jul/24
Ambu A/S 68.15 0.65 0.96% -32.86% Jul/24
Amplifon 11.03 0.10 0.87% -45.37% Jul/24
Apollo Hospitals Enterprise Ltd 8,805.50 -56.50 -0.64% 17.90% Jul/24
Avanos Medical 24.99 0.01 0.04% 108.08% Jul/24
Brookdale Senior Living 15.15 0.65 4.45% 101.66% Jul/24
Coloplast 403.60 4.80 1.20% -34.73% Jul/24
Cencora 309.89 4.83 1.58% 6.73% Jul/24
Convatec Group 216.00 3.40 1.60% -9.85% Jul/24

Indexes Price Day Year Date
US500 7412 3.69 0.05% 16.02% Jul/24
US100 28128 -326.47 -1.15% 20.87% Jul/24

GE HealthCare Technologies traded at $60.59 this Friday July 24th, decreasing $1.40 or 2.26 percent since the previous trading session. Looking back, over the last four weeks, GE HealthCare Technologies lost 6.70 percent. Over the last 12 months, its price fell by 21.93 percent. Looking ahead, we forecast GE HealthCare Technologies to be priced at 59.31 by the end of this quarter and at 55.64 in one year, according to Trading Economics global macro models projections and analysts expectations.

GE HealthCare Technologies Inc. is a medical technology, pharmaceutical diagnostics, and digital solutions company. The Company provides integrated solutions, services, and data analytics. Its segments include Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a comprehensive portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its Ultrasound segment includes ultrasound medical devices and solutions with a portfolio of continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. The segment also includes the clinical artificial intelligence (AI) software business. Its PCS segment portfolio consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment consists of two business lines: contrast media and molecular imaging.